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Summary
This paper describes a convergent mechanism for the feedback control of cholesterol synthesis and uptake mediated by
SREBPs, membrane bound transcription factors. Endoplasmic reticulum (ER) bound SREBPs form complexes with Scap, a
polytopic ER protein. In sterol-overloaded cells, Scap/SREBP binds to Insig-1, which retains the complex in the ER. Upon
sterol deprivation, the Scap/SREBP complex dissociates from Insig-1, which is then ubiquitinated on lysines 156 and 158
and degraded in proteasomes. Scap/SREBP moves to the Golgi, where SREBP is processed to liberate a nuclear fragment
that activates genes for cholesterol synthesis and uptake and the gene for Insig-1. Ubiquitination is not necessary for release
of Scap/SREBP from Insig-1, but it establishes a requirement for synthesis of new Insig-1 for feedback inhibition. When the
new Insig-1 and cholesterol converge on Scap, Scap/SREBP binds to Insig-1, preventing ubiquitination. The Insig-1/Scap/
SREBP complex accumulates in the ER, ready for liberation when the cell is again sterol deprived.Introduction
Insigs are polytopic membrane proteins of the endoplasmic re-
ticulum (ER) that regulate lipid synthesis by retaining sterol reg-
ulatory element binding proteins (SREBPs) in the ER and pre-
venting their proteolytic activation in the Golgi apparatus (Yang
et al., 2002; Yabe et al., 2002). SREBPs are transcription factors
that are synthesized as integral ERmembrane proteins. Immedi-
ately after synthesis, they form tight complexes with Scap,
a membrane-embedded escort protein (Brown and Goldstein,
1999). When membrane cholesterol levels are low, the Scap/
SREBP complex is incorporated into COPII-coated vesicles that
bud from the ER and carry the SREBPs to the Golgi, where the
concerted actions of two proteases release the transcription-
factor portion of the SREBP into the cytosol, fromwhich it enters
the nucleus (Nohturfft et al., 2000; Espenshade et al., 2002; Sun
et al., 2005). There, the SREBPs activate transcription by binding
to sterol regulatory elements in the enhancers of more than
20 genes that produce enzymes required for synthesis of cho-
lesterol and its uptake by low-density lipoprotein (LDL) recep-
tors (Horton et al., 2003). When cholesterol accumulates in ER
membranes, the sterol binds to Scap (Radhakrishnan et al.,
2004), altering its conformation and causing the Scap/SREBP
complex to bind to Insigs (Brown et al., 2002; Adams et al.,
2004).
When the Scap/SREBP complex binds to Insigs, it can no lon-
ger be incorporated into COPII-coated vesicles (Sun et al.,
2005). The ER-retained SREBPs cannot be processed, and tran-
scription of the target genes declines. This feedback-suppres-
sion mechanism allows cholesterol to control its own synthesis
and uptake, and it ensures a steady level of cholesterol in cell
membranes (Goldstein et al., 2002). Binding of Scap/SREBP
complexes to Insigs can also be triggered by certain oxygen-
ated derivatives of cholesterol, including 25-hydroxycholesterol
(25-HC) (Adams et al., 2004).CELL METABOLISM 3, 15–24, JANUARY 2006 ª2006 ELSEVIER INC.Because the formation of Scap/SREBP/Insig complexes is
stoichiometric rather than catalytic, the sterol regulatory system
depends on the relative amounts of Scap and Insig in ER mem-
branes. Under artificial conditions, relative overexpression of
Scap saturates endogenous Insigs, and the excess Scap trans-
ports SREBPs to the Golgi, even in the presence of sterols (Yang
et al., 2002). On the other hand, overexpression of Insigs causes
the Scap/SREBP complex to be retained in the ER even at low
levels of cellular cholesterol, thereby inappropriately limiting
cholesterol synthesis (Yang et al., 2002; Yabe et al., 2002; En-
gelking et al., 2005). To prevent these imbalances, elaborate
transcriptional and posttranscriptional mechanisms control the
concentration of Insigs.
Cells express two Insig genes that encode proteins that are
59% identical and appear to serve redundant functions (Yabe
et al., 2002; Engelking et al., 2005). The two Insig proteins differ
in their mechanisms of control. Insig-1 is an SREBP target gene
(Yang et al., 2002; Horton et al., 2002). Its mRNA is expressed
at high levels when nuclear SREBP levels are high as a result
of sterol deprivation. Because of this dependence on SREBPs,
Insig-1 mRNA levels decline drastically when cells are over-
loaded with sterols. In cultured cells, the amount of Insig-2 is
lower than that of Insig-1, even when the cells have been over-
loaded with sterols. Importantly, Insig-2 is not regulated by
SREBPs, and hence it persists when cells are overloaded with
sterols and SREBPs are excluded from the nucleus (Sever
et al., 2004; Lee et al., 2005).
Recently, a new level of potential control was uncovered with
the observation that Insig-1 is degradedmuchmore rapidly than
Insig-2 (Lee and Ye, 2004). This rapid turnover of Insig-1 oc-
curred when protein synthesis was blocked in cultured cells
by exposing them to hypotonic stress, causing a rapid disap-
pearance of Insig-1. In the current studies, we have sought to
determine whether the rapid degradation of Insig-1 is regulated.
The results indicate that Insig-1 is rapidly ubiquitinated andDOI 10.1016/j.cmet.2005.11.014 15
A R T I C L EFigure 1. Sterol-regulated degradation of 35S-labeled Insig-1 in hamster cells
A)On day 0, CHO-7 cells were set up at 7.53 105 cells per 60 mm dish in medium
A with 5% LPDS. On day 1, cells were refed with sterol-depleting medium B. After
16 hr, cells were preincubated for 1 hr in methionine- and cysteine-free medium D,
after which they were pulse labeled for 1 hr with 200 mCi/ml 35S Protein Labeling
Mix in medium D. Cells were then washed and incubated in medium B (containing
unlabeled methionine and cysteine) in the absence (2) or presence (+) of 1 mg/ml
25-HC. Following the indicated incubation period, cells were harvested and lysed,
and the whole-cell lysates were subjected to immunoprecipitation with polyclonal
antiserum against Insig-1 (1:100 dilution). Aliquots of immunoprecipitates were
subjected to 12% SDS-PAGE and transferred to nitrocellulose filters. Filters
were exposed for 24 hr to an imaging plate at room temperature and scanned
as described in Experimental Procedures.
B) Quantification of 35S radioactivity corresponding to Insig-1 in (A). The intensity
of Insig-1 during the pulse (zero time value) was arbitrarily set at 100%.
Figure 2. Inhibition of degradation of endogenous and transfected Insig-1 by 25-
hydroxycholesterol in hamster cells
A)On day 0, CHO-7 cells were set up at 53 105 cells per 100mmdish inmedium A
supplemented with 5% LPDS. On day 2, cells were refed with sterol-depleting me-
dium B. After 16 hr (see schematic), cells were switched to fresh medium B con-
taining 50 mM cycloheximide (CHX) in the absence (2) or presence (+) of 1 mg/ml
of 25-HC. At the indicated time after CHX exposure, cells were harvested, and ali-
quots of whole-cell lysates were subjected to 10% SDS-PAGE and immunoblot
analysis with a 1:1000 dilution of polyclonal antiserum against Insig-1.
B) On day 0, SRD-14/pTK-Insig1-Myc cells were set up at 5 3 105 cells per 100
mmdish in medium Awith 5% LPDS. On day 2, cells were refed with sterol-deplet-
ing medium B. After 16 hr (see schematic), cells were switched to fresh medium B
containing 50 mMCHX in the absence (2) or presence (+) of 1 mg/ml 25-HC. At the
indicated time after CHX addition, cells were harvested and fractionated, and ali-
quots of whole-cell lysates were subjected to 10% SDS-PAGE and immunoblot
analysis with 2 mg/ml monoclonal anti-Myc IgG against Insig-1. In (A) and (B), filters
were exposed to film for 30 s.degraded only when it is free from Scap and that sterol-induced
binding of Insig-1 to Scap prevents Insig-1 ubiquitination and
degradation. These results lead to a new model for the conver-
gent inhibition of SREBP processing and cholesterol supply in
animal cells.
Results
Insig-1 protein is stabilized by sterols
Figure 1 shows a pulse-chase experiment demonstrating that
Insig-1 is rapidly degraded in sterol-depleted cells and that
this degradation is blocked by sterols in the form of 25-HC.
Wild-type CHO cells were depleted of sterols by prior incubation
in medium containing lipoprotein-deficient serum (LPDS), the
sterol synthesis inhibitor compactin (an inhibitor of 3-hydroxy-
3-methylglutaryl coenzyme A reductase [HMG CoA reductase]),
and a low concentration of mevalonate to prevent depletion of
nonsterol endproducts (Goldstein and Brown, 1990). The cells
were then pulse labeled with [35S]methionine plus [35S]cysteine
and chased in isotope-free medium. Insig-1 was isolated by
immunoprecipitation, subjected to SDS-PAGE, and the 35S-
labeled protein was visualized in a phosphorimager. Insig-1
gives two bands on SDS-PAGE (Figure 1A) owing to the use of
alternative translation initiation sites (Yang et al., 2002). In the ab-16sence of sterols, the 35S-labeled Insig-1 was rapidly degraded,
with a half-life of w20 min (Figure 1B). Addition of 25-HC pre-
vented this degradation.
To study Insig-1 degradation without radioisotopes, we used
SDS-PAGE and immunoblotting to follow the disappearance of
total Insig-1 after protein synthesis was blocked by cyclohexi-
mide (CHX) (Figure 2). In the absence of sterols, endogenous
Insig-1 disappeared from wild-type CHO cells within 30 min af-
ter CHX addition (Figure 2A, lanes 1–5). This rapid degradation
was blocked by 25-HC (Figure 2A, lanes 6–10). Similar results
were obtained when we used CHX to follow the degradation
of epitope-tagged Insig-1 that was produced by transfection
from a constitutive nonregulated promoter (Figure 2B).
Sterol stabilization of Insig-1 requires Scap
Figure 3A shows that the ability of 25-HC to stabilize Insig-1 de-
pends on the presence of Scap. For this purpose, we used SRD-
13A cells, a line of mutant CHO-7 cells in which both copies of
the Scap gene are nonfunctional (Rawson et al., 1999). When
these cells were transfected with pTK-Insig1-Myc and incu-
bated in sterol-depleting medium, the Myc-tagged protein was
degraded rapidly after CHX treatment (Figure 3A, lanes 1–3),
and there was no stabilization by 25-HC (lanes 4–6). When
wild-type Scap was coexpressed, the degradation of Insig-1CELL METABOLISM : JANUARY 2006
Sterol-regulated degradation of Insig-1was retarded even in the absence of 25-HC (lanes 7–9), likely be-
cause the cells contained a low level of residual sterols. Degrada-
tion was further blocked when 25-HC was added (lanes 10–12).
To confirm that Scap binding mediates the stabilization of
Insig-1, we transfected the SRD-13A cells with a plasmid en-
coding Scap(Y298C), a mutant Scap that does not bind to Insigs
(Adams et al., 2004). In SRD-13A cells producing Insig-1-Myc
Figure 3. Slowing of Insig-1 degradation requires sterol-dependent interaction
with Scap and is blocked by proteasome inhibitors
On day 0, Scap-deficient SRD-13A cells were set up at 3.5 3 105 cells per 60 mm
dish in medium C.
A) On day 2, cells were transfected in 3 ml of medium A containing 5% FCS with
1 mg pTK-Insig1-Myc (lanes 1–12) with (lanes 7–12) or without (lanes 1–6) 1 mg pTK-
Scap as indicated. The total DNA in each dish was adjusted to 3 mg by addition of
pcDNA3 mock vector. Six hours after transfection, cells were refed with sterol-
depleting medium B. After 16 hr (see schematic), cells were switched to fresh me-
dium B containing 50 mM CHX in the absence (2) or presence (+) of 1 mg/ml of
25-HC. At the indicated time after CHX treatment, cells were harvested and frac-
tionated, and aliquots of whole-cell lysates were subjected to SDS-PAGE and im-
munoblot analysis with 5 mg/ml of monoclonal anti-Myc IgG (against Insig-1) and
5 mg/ml polyclonal IgG-R139 (against Scap). Filters were exposed to film for
30 s (lanes 1–6) and 5 s (lanes 7–12) for Insig-1 and 1 min for Scap (lanes 1–12).
B) On day 2, cells were transfected in 3 ml of medium A containing 5% FCS with
0.2 mg pTK-Insig1-Myc and 1 mg of either wild-type (wt) pTK-Scap or a mutant ver-
sion (Y298C) as indicated. The total DNA was adjusted to 3 mg/dish by addition of
pcDNA3 mock vector. Six hours after transfection, cells were refed with sterol-
depleting medium B. After 16 hr (see schematic), cells were switched to fresh me-
diumB containing 10 mMMG-132 (lanes 7–12) in the absence (2) or presence (+) of
1 mg/ml 25-HC. After incubation for 5 hr, cells were harvested and fractionated,
and aliquots of whole-cell lysates were subjected to 8 or 10% SDS-PAGE and
immunoblot analysis with 5 mg/ml of monoclonal anti-Myc IgG (against Insig-1)
and 5 mg/ml polyclonal IgG-R139 (against Scap). Filters were exposed to film for
5 s (Insig-1) or 1 min (Scap).CELL METABOLISM : JANUARY 2006alone, Insig-1-Myc levels were low in either the absence or
presence of 25-HC (Figure 3B, lanes 1 and 2). Coexpression
of wild-type Scap stabilized Insig, even in the absence of exog-
enous sterols (lane 3), and stabilization was increased by 25-HC
(lane 4). Coexpression of Scap(Y298C) did not stabilize Insig-1,
even in the presence of 25-HC (lanes 5 and 6). Immunoblotting
with an antibody against Scap confirmed that equal amounts
of wild-type and Y298C were expressed (Figure 3B, bottom
panel, lanes 3–6). When we incubated the cells with MG-132,
an inhibitor of the proteasome, Insig-1 became visible even in the
absence of Scap (lanes 7) and in cells expressing Scap(Y298C)
(lane 11), and there was no further effect of 25-HC (lanes 8, 10,
and 12). These data indicate that Insig-1 is rapidly degraded
by a proteasomal process and that full stabilization requires the
presence of 25-HC and a form of Scap that is capable of binding
to Insig.
Ubiquitination precedes Insig-1 degradation
Proteasomal degradation of a protein requires prior ubiquitina-
tion (Hershko and Ciechanover, 1998). To demonstrate ubiquiti-
nation of Insig-1, we transfected Scap-deficient SRD-13A cells
with a plasmid encoding Insig-1 and a plasmid encoding ubiqui-
tin that contains an HA epitope tag. The cells were incubated in
sterol-depleting medium, after which some of the dishes re-
ceived 25-HC. For 2 hr prior to harvest, the cells were incubated
with MG-132 to block the degradation of ubiquitinated Insig-1.
Insig-1 was immunoprecipitated from detergent-solubilized ly-
sates, and the precipitates were subjected to SDS-PAGE and
blotted with an antibody to the HA tag on ubiquitin. In control
cells not expressing T7-tagged Insig-1, no ubiquitin was seen
in the Insig-1 immunoprecipitates (Figure 4A, lane 1). In cells ex-
pressing the tagged Insig-1, the anti-ubiquitin blot of the Insig-1
immunoprecipitate exhibited the typical smear seen with poly-
ubiquitinated proteins (lane 2). Themost rapidlymigrating bands
consisted of a doublet that migrated at the same position as
authentic Insig-1. Since they were visualized with the anti-HA
antibody, these bands likely represented Insig-1 that contained
a minimal number of ubiquitins. In the absence of Scap, the ad-
dition of 25-HC did not affect Insig-1 ubiquitination (lane 3). Co-
expression of Scap did not affect Insig-1 ubiquitination in the ab-
sence of sterols (lane 4), but it permitted 25-HC to block this
ubiquitination (lane 5). Although ubiquitinated Insig-1was clearly
seen when blotted with the antibody against the HA tag in ubiq-
uitin, we did not see a higher-molecular-weight smear (data not
shown) when we blotted with an antibody against the T7 tag on
Insig-1 (IB: Insig-1 in Figure 4A). Although Figure 4A shows only
a portion of the Insig-1 immunoblot, we also did not observe
a smear when the whole autoradiogram was examined. This is
the usual finding in studies of protein ubiquitination in intact
cells, and it is believed to reflect the activity of deubiquitinating
enzymes that remove the ubiquitin when cell extracts are made.
The amount of residual ubiquitinated Insig-1 is sufficient for
visualization when blotted for ubiquitin but not when blotted
for Insig-1.
We reasoned that ubiquitination of Insig-1 likely occurs on ly-
sine residues oriented toward the cytoplasm. Insig-1 is pre-
dicted to contain four such residues at positions 33, 156, 158,
and 273 (Feramisco et al., 2004). In preliminary mutagenesis ex-
periments, we determined that the lysines at positions 33 and
273 could be changed to arginines without affecting ubiquitina-
tion (data not shown). However, the closely spaced lysines at17
A R T I C L EFigure 4. Lysine 156 and lysine 158 are required for
sterol-mediated ubiquitination and degradation of
Insig-1 in hamster cells
A) On day 0, Scap-deficient SRD-13A cells were set
up at 3.5 3 105 cells per 60 mm dish in medium C.
On day 2, cells were transfected in 3 ml of medium
A containing 5% FCS with 0.2 mg of pEF1a-HA-
ubiquitin, 0.2 mg pCMV-Insig1-T7, and 1 mg of
pCMV-Scap as indicated. The total DNA in each
lanewas adjusted to 3mg/dish by addition of pcDNA3
mock vector. Six hours after transfection, cells were
refed with sterol-depleting medium B. After 16 hr,
cellswere switched to freshmediumB in the absence
(2) or presence (+) of 1 mg/ml of 25-HC. After incuba-
tion for 3 hr, each dish received 10 mMMG-132. Fol-
lowing incubation at 37ºC for 2 hr, cells were har-
vested and subjected to immunoprecipitation with
monoclonal anti-T7 IgG-coupled agarose beads. Ali-
quots of cell lysates and immunoprecipitates were
subjected to SDS-PAGE (6% for ubiquitin blot, 8%
for Scap, 10% for Insig-1) and immunoblot analysis
with 1:1000dilution of polyclonal anti-HA IgG (against
ubiquitin), 1:15,000 dilution of polyclonal anti-T7 IgG
(against Insig-1), and 5 mg/ml polyclonal IgG-R139
(against Scap). Filters were exposed to film for 5 s.
B) On day 0, SRD-13A cells were set up as in (A). On
day 2, cellswere transfected in 3ml ofmediumAcon-
taining 5% FCS with 0.2 mg of pEF1a-HA-ubiquitin
and/or 0.2 mg of wt pCMV-Insig1-T7 or a mutant (m)
version (K156R/K158R) as indicated. The total DNA
in each lane was adjusted to 3 mg/dish by addition
of pcDNA3 mock vector. After 16 hr, each dish re-
ceived 10 mM MG-132. Following incubation at
37ºC for 2 hr, cells were harvested and subjected to
immunoprecipitation, SDS-PAGE, and immunoblot
analysis as above. Filters were exposed to film for
2–20 s.
C) On day 0, SRD-14/pTK-Insig1-Myc cells (lanes
1–10) and SRD-14/pTK-Insig1(K156R/K158R)-Myc
cells (lanes 11–20) were set up at 5 3 105 cells per
100 mm dish in medium A with 5% LPDS. On day 2,
cells were refed with sterol-depleting medium B. Af-
ter 16 hr, cells were switched to freshmediumB con-
taining 50 mMCHX in the absence (2) or presence (+)
of 1 mg/ml of 25-HC. At the indicated time after CHX
treatment, cells were harvested and fractionated,
and aliquots of whole-cell lysates were subjected to
10% SDS-PAGE and immunoblot analysis with 2
mg/ml of monoclonal anti-Myc IgG against Insig-1.
Filters were exposed to film for 30 s (lanes 1–10)
and 2 s (lanes 11–20).residues 156 and 158 were crucial. Figure 4B shows that wild-
type Insig-1 was ubiquitinated as determined by immunoprecip-
itation of Insig-1 followed by blotting with anti-HA ubiquitin (lane
4). No ubiquitination was demonstrated when we expressed a
plasmid encoding a mutant of Insig-1 with arginines substituted
for lysines at positions 156 and 158 (lane 5). The bottom autora-
diogramof Figure 4B shows that equal amounts of wild-type and
mutant Insigs were precipitated with the antibody against the T7
epitope on the Insigs. Mutant Insig-1 with only a single lysine
mutation (K156R or K158R) was degraded as rapidly as wild-
type Insig-1, suggesting that ubiquitination on either lysine is
sufficient for proteasomal degradation (data not shown).
Ubiquitination of Insig-1 is not required
for its dissociation from Scap
If ubiquitination is required for rapid degradation of Insig-1, then
the K156R/K158Rmutant should not be degraded, and it should18not require Scap and 25-HC for stabilization. To test this hypoth-
esis, we used SRD-14 cells, a line of mutant CHO cells that does
not express Insig-1 but does express Scap (Sever et al., 2004).
We transfected the SRD-14 cells with plasmids encoding wild-
type Insig-1 or the K156R/K158R mutant under control of the
thymidine kinase (TK) promoter. Stable lines expressing wild-
type and mutant Insig-1 were prepared. In the absence of
sterols, immunoblottable wild-type Insig-1 protein became un-
detectable within 60 min after CHX addition (Figure 4C, lanes
1–5), whereas no such disappearance was seen with the
K156R/K158R Insig-1 mutant (lanes 11–15).
The question immediately arises as to whether ubiquitination
and degradation of Insig-1 are essential to release the Scap/
SREBP complex or whether the complex can be released upon
sterol deprivation even when ubiquitination and degradation do
not occur. To answer this question, we studied the SRD-14 cells
that were stably transfected with the cDNAs encoding eitherCELL METABOLISM : JANUARY 2006
Sterol-regulated degradation of Insig-1Figure 5. Time course of SREBP cleavage in Insig-
1-deficient hamster cells stably transfected with
wild-type or mutant Insig-1 after gradual or acute de-
pletion of sterols
On day 0, SRD-14/pTK-Insig1-Myc cells (lanes 1–5)
and SRD-14/pTK-Insig1(K156R/K158R)-Myc cells
(lanes 6–10) were set up at 7 3 105 cells per 60
mm dish in medium A with 5% LPDS. On day 1, cells
were refed with medium A containing 5% LPDS and
0.3 mg/ml of 25-HC.
A) After incubation for 12 hr with 25-HC, the cells
were washed and then switched to sterol-free me-
dium B for the indicated time.
B) After cells were incubated for 16 hr with 25-HC,
the cells were treated with 1% (w/v) hydroxypropyl-
b-cyclodextrin (HPCD) in sterol-free medium B for
15 min, then washed and switched to sterol-free me-
dium B for the indicated time. In (A) and (B), the
switch in medium was staggered such that all the
cells could be harvested at the same time and di-
vided into two groups. One group of cells was frac-
tionated, and aliquots of whole-cell lysates were
subjected to 8 or 10% SDS-PAGE and immunoblot
analysis with 1 mg/ml of monoclonal anti-Myc IgG
(against Insig-1) and 5 mg/ml of monoclonal IgG-
7D4 (against SREBP-2). P and N denote precursor
and nuclear forms of SREBP-2, respectively. The
second group of cells was immunoprecipitated (IP)
with 40 mg/ml polyclonal anti-Myc against Insig-1
as described in Experimental Procedures. Immuno-
precipitated pellets (representing 0.25 dish of cells)
and supernatants (representing 0.05 dish of cells)
were subjected to 8 or 10% SDS-PAGE and immu-
noblotted (IB) with 5 mg/ml monoclonal IgG-9D5
(against Scap) and 1 mg/ml anti-Myc monoclonal
IgG (against Insig-1). Filters were exposed to film
for 2–60 s.wild-type Insig-1 or the K156R/K158Rmutant. We tested the re-
sponse of these cells to two types of sterol depletion: (1) gradual
depletion by incubating the cells in serum from which the cho-
lesterol-carrying lipoproteins had been removed (LPDS) (Fig-
ure 5A) and (2) rapid depletion by incubating the cells in hydroxy-
propyl-b-cyclodextrin (HPCD) (Figure 5B). Prior to the start
of both experiments, the cells were incubated with 25-HC to
form the stable Insig-1/Scap/SREBP complex. The amount of
Insig-1 and the amount of Scap that coimmunoprecipitated
with Insig-1 were measured. We also measured the amount of
nuclear SREBP-2. In the gradual sterol-depletion experiment
(Figure 5A), in cells expressing wild-type Insig-1, the amount
of Insig-1 began to decline as early as 4 hr after initiating sterol
depletion. At this time point, there was a modest decline in theCELL METABOLISM : JANUARY 2006amount of Scap that coimmunoprecipitated with Insig-1, and
a trace of nuclear SREBP-2 appeared (lane 2). By 8 hr, Insig-1
had declined further, we no longer visualized any Scap immuno-
precipitating with Insig-1, and nuclear SREBP-2 was clearly de-
tectable (lane 3). A delay in these processeswas seen in the cells
expressing the K156R/K158R mutant. At 8 hr, the amount of the
mutant Insig-1 remained high, abundant Scap continued to
coimmunoprecipitate with the Insig-1, and nuclear SREBP-2
was still not visible (lane 8). By 24 hr, the mutant Insig-1 had de-
clined, the amount of Scap in the immunoprecipitate fell, and nu-
clear SREBP-2 was clearly visible (lane 10). These data suggest
that, under conditions ofmild sterol depletion, the failure to ubiq-
uitinate Insig-1 causes a delay in release of the Scap/SREBP-2
complex, but it does not abolish it.19
A R T I C L ETo test the role of ubiquitination under more extreme condi-
tions, we treated the cells with hydroxypropyl-b-cyclodextrin to
deplete sterols acutely (Figure 5B). This treatment hastened the
entire process. In cells expressing wild-type Insig-1, the amount
of Insig-1 declined markedly within 1 hr (lane 1). At this point,
Scap no longer coimmunoprecipitated with Insig-1, and nuclear
SREBP-2 was clearly visible. In cells expressing the K156R/
K158R mutant, the amount of the mutant Insig-1 protein re-
mained high throughout the experiment (lanes 6–10). Neverthe-
less, within 1 hr, Scap no longer immunoprecipitated with
Insig-1, and nuclear SREBP-2 was already being generated
(lane 8).
Cholesterol and new Insig-1 converge on Scap
to suppress SREBP cleavage
The data of Figure 5B indicate that, upon severe sterol deple-
tion, the Scap/SREBP complex can dissociate from Insig-1
even when Insig-1 is not ubiquitinated or degraded. Thus, ubiq-
uitination of Insig-1 is not required in order for Insig-1 to release
Scap. What, then, is the role of ubiquitination and degradation?
We hypothesized that this degradation is necessary in order to
establish a condition in which SREBP processing can only be
terminated when SREBPs have entered the nucleus, activated
the Insig-1 gene, and restored the level of Insig-1 protein.
To test this hypothesis, we performed sterol-depletion experi-
ments in wild-type cells that express Insig-1 from its natural pro-
moter (Figures 6A–6D). In Figures 6A and 6B, wild-type CHO-7
cells were preincubated with 25-HC and then treated for 15
min with cyclodextrin to deplete sterols, followed by incubation
in medium with LPDS. At zero time, Insig-1 was present, and
there was no detectable nuclear SREBP-2 (Figure 6A). Insig-1
protein was observed despite a relatively low level of Insig-1
mRNA as measured by quantitative real-time PCR (see bar
graph in Figure 6B), presumably because Insig-1 was protected
from degradation by formation of the sterol-dependent Scap/
Insig-1 complex. Within 0.75 hr of sterol depletion, most of the
Insig-1 had been degraded, nuclear SREBP-2 became visible,
and the amount of Insig-1 mRNA had risen by 3-fold owing to
transcriptional stimulation by nuclear SREBPs. The amount of
Insig-1 protein began to increase as the level of Insig-1 mRNA
rose. At 1.5 hr, FCSwas added to the culture medium. FCS con-
tains LDL, which supplies cholesterol to cells via the LDL recep-
tor (Goldstein et al., 1983). At 5.5 hr, the amount of nuclear
SREBP-2 began to decline, presumably owing to the formation
of the cholesterol/Scap/Insig-1 complex. In response to the de-
cline in nuclear SREBPs, the amount of Insig-1 mRNA declined
but the amount of Insig-1 protein remained high owing to its
complex with Scap.
The data of Figures 6A and 6B, together with previous data in
this paper, indicate that, upon acute sterol deprivation, the in-
crease in nuclear SREBPs stimulates the uptake and synthesis
of cholesterol as well as the synthesis of new Insig-1 molecules.
The convergence of cholesterol and Insig-1 traps the Scap/
SREBP complex in the ER, leading to a decline in nuclear
SREBPs and Insig-1 mRNA, but a persistence of Insig-1 protein,
owing to the stability of its complex with Scap. To confirm that
cholesterol uptake is required for this convergent effect, we re-
peated the sterol-depletion experiment, but this time we incu-
bated the cells in lipoprotein-deficient serum (LPDS) instead of
FCS. In contrast to FCS, LPDS is devoid of LDL, and it cannot
supply cholesterol to the cells. The results are shown in Figures206C and 6D.When cells were depleted of sterols and then placed
in FCS, Insig-1 protein initially declined and nuclear SREBP-2 in-
creased (Figure 6C). Thereafter, the reciprocal changes oc-
curred, i.e., Insig-1 protein rose and nuclear SREBP-2 declined.
These resultsduplicate thefindingsof Figure6A.When thesterol-
depleted cells were incubated in LPDS, the initial response was
the same, i.e., Insig-1 fell and nuclear SREBP-2 increased (Fig-
ure 6D). However, in the absence of LDL cholesterol, the sub-
sequent rise in Insig-1 was delayed and there was no fall in nu-
clear SREBP-2. This result indicates that the cells require the
convergence of cholesterol and Insig-1 in order to block SREBP
processing. Endogenous cholesterol synthesis is not sufficient
to satisfy the cholesterol requirement over the short term of this
experiment, and therefore, LDL-derived cholesterol is essential.
Figures 6E and 6F show the result opposite to that in Figures
6A–6D—namely, the response of sterol-depleted CHO cells to
the addition of 25-HC. In this experiment, the cells were preincu-
bated in LPDS to deplete sterols, and then 25-HCwas added. At
zero time, the sterol-deprived cells contained a relatively small
amount of Insig-1 protein, no Scap was coimmunoprecipitated
with Insig-1, and the content of nuclear SREBP-2 was high (Fig-
ure 6E). The amount of Insig-1mRNAwas also high, presumably
owing to the high level of nuclear SREBPs (Figure 6F). Within
0.5 hr after adding 25-HC, the amount of Insig-1 protein had
risen detectably, Scap became visible in the Insig-1 immunopre-
cipitate, and the amount of nuclear SREBP-2 had begun to
decline. Insig-1 mRNA remained high. By 1 hr, Insig-1 protein
reached a peak, as did the amount of Scap in the Insig-1 immu-
noprecipitate. Nuclear SREBP-2 was reduced by more than
90%. The fall in Insig-1 mRNA levels lagged behind the drop
in nuclear SREBP-2, apparently owing to the half-life of the
mRNA, but by 3 hr the Insig-1 mRNA had declined by more
than 90%. Despite this decline in mRNA, the Insig-1 protein
was accumulating, presumably owing to its stabilization in the
Scap/Insig-1 complex. At the conclusion of the experiment
(4 hr), the level of Insig-1 protein was the same as it was at
zero time even though Insig-1 mRNA had declined by 95%.
Discussion
The data in this paper, together with previous data from this lab-
oratory, establish a model for the control of cholesterol supply
that we call ‘‘convergent feedback inhibition.’’ The essential
elements are diagrammed in Figure 7. In sterol-depleted cells,
cholesterol dissociates from the Scap/SREBP complex, and
this causes Insig-1 to dissociate as well. The liberated Insig-1
undergoes ubiquitination at lysines 156 and 158, which leads
to proteasomal degradation. The liberated Scap/SREBP com-
plex binds to COPII proteins, which cluster it into COPII-coated
vesicles for transport to the Golgi. In the Golgi, the SREBP is
processed by proteases to release the transcriptionally active
NH2-terminal domain, which moves to the nucleus, where it ac-
tivates transcription of all of the genes that encode enzymes re-
quired for cholesterol synthesis and for uptake through the LDL
receptor (Horton et al., 2002). As a result, the cell synthesizes
cholesterol and takes it up from LDL to correct the deficit. At
the same time, nuclear SREBP enhances transcription of the
Insig-1 gene, and the resultant Insig-1 protein is inserted into
the ER membrane. The newly synthesized Insig-1 will be de-
graded rapidly unless the cell has accumulated sufficient choles-
terol to alter the conformation of Scap so that it binds Insig-1,CELL METABOLISM : JANUARY 2006
Sterol-regulated degradation of Insig-1Figure 6. Levels of endogenous Insig-1 protein and mRNA in hamster cells at different times after sterol depletion and repletion
A–D) Time course after acute sterol depletion with cyclodextrin followed by incubation with (A–C) or without (D) FCS. On day 0, CHO-7 cells were set up at 53 105 cells per
100 mm dish in medium A supplemented with 5% LPDS. On day 2, cells were refed with medium A containing 5% LPDS and 0.3 mg/ml of 25-HC. After incubation for 16 hr,
the cells were treated with 1% (w/v) hydroxypropyl-b-cyclodextrin (HPCD) in sterol-free medium A supplemented with 5% LPDS for 15 min, then washed and switched to
the same sterol-free mediumwithout HPCD for the indicated time. At 1.5 hr after treatment with HPCD, the cells were switched tomedium A supplemented with either 10%
FCS (A–C) or 5% LPDS (D). The switch in medium was staggered such that all of the cells could be harvested at the same time. In (A), (C), and (D), cells were harvested and
aliquots of whole-cell lysates were subjected to 8 or 10% SDS-PAGE and immunoblot analysis with a 1:1000 dilution of polyclonal antiserum (against Insig-1) and 5 mg/ml
monoclonal IgG-7D4 (against SREBP-2). P and N denote precursor and nuclear forms of SREBP-2, respectively. Filters were exposed to film for 10 s (Insig-1) or 60 s
(SREBP-2). In (B), cells were harvested and total RNA was isolated from duplicate dishes, pooled, and subjected to reverse transcription as described in Experimental
Procedures. Insig-1 mRNA was determined by quantitative real-time PCR. Values are presented in arbitrary units relative to the zero-time value, which is set at 1.
E and F) Time course after addition of 25-hydroxycholesterol. On day 0, CHO-7 cells were set up at 5 3 105 cells per 100 mm dish in medium A supplemented with 5%
LPDS. On day 2, cells were refed with medium B. After 16 hr in sterol-free medium, cells were switched to medium B containing 1 mg/ml of 25-HC. After incubation with 25-
HC for the indicated time, the cells were processed for immunoblot analysis (E) and mRNA levels (F) as described above.forming a stable complex that remains in the ER and resists
ubiquitination and degradation. The process is convergent be-
cause SREBP processing will not be blocked unless two SREBP
products converge on Scap simultaneously: (1) newly synthe-
sized Insig-1 and (2) newly acquired cholesterol. This require-
ment for convergence assures that SREBP processing will not
be terminated prematurely before the SREBP has acted in the
nucleus to increase Insig-1 mRNA and to replenish cell choles-
terol levels.CELL METABOLISM : JANUARY 2006Although ubiquitination is required for rapid Insig-1 degrada-
tion, it is not required for release of the Scap/SREBP complex.
Thus, upon severe sterol depletion, the Scap/SREBP complex
is released even when the cells express a mutant Insig-1 that
is not ubiquitinated or degraded (Figure 5B). This result is differ-
ent from that for NF-kB, a soluble transcription factor that is held
out of the nucleus by binding to one of several IkB proteins. Nu-
clear entry of NF-kBoccurs only after IkBhas been ubiquitinated
and degraded (Hoffmann et al., 2002; Chen, 2005).21
A R T I C L EIn order for the convergent feedback mechanism of choles-
terol control to operate, two conditions must be met: (1) Insig-1
must be destroyed after sterol depletion, and (2) SREBPs must
activate the synthesis of replacement Insig-1 molecules as well
as the genes supplying cholesterol. Destruction of Insig-1 cre-
ates a requirement for newly synthesized Insig-1, which cannot
occur unless sufficient SREBP molecules have entered the nu-
cleus. Thus, sterol synthesis will not be suppressed unless
SREBPs have acted on two processes: (1) cholesterol supply
through de novo synthesis and uptake via LDL receptors and
(2) Insig-1 gene transcription.
The significance of the two components of the Insig-1 control
mechanism is underscored by a comparison with Insig-2. In
contrast to Insig-1, Insig-2 is neither rapidly degraded nor a tran-
scriptional target of SREBPs. The fact that Insig-1 uniquely pos-
sesses both attributes emphasizes the necessity for rapid, ste-
rol-regulated degradation coupled to transcriptional activation
in order for the convergent control mechanism to operate.
If Insig-2 does not participate in convergent feedback, what is
its role? Studies of mutant CHO cells suggest that Insig-2 func-
tions in long-term control of SREBP processing. Thus, SRD-14
cells lack Insig-1 as a result of loss of function of both alleles of
the Insig-1 gene, but they express normal amounts of Insig-2
protein (Sever et al., 2004). In SRD-14 cells, 25-HC fails to block
SREBP processing acutely within 5 hr after exposure. However,
after 14 hr, SREBP-2 processing is blocked. Thus, at normal
levels of expression, Insig-2 cannot replace Insig-1 in achieving
short-term control of SREBP processing. The long-term func-
tion of Insig-2may help to smooth out oscillations in SREBP pro-
cessing that might otherwise occur as Insig-1 levels rise and fall
through the convergent feedback mechanism. This would be
analogous to the roles of the several isoforms of IkB, a family
of proteins that play roles in the NFkB pathway (Hoffmann
et al., 2002) that are similar to those of Insigs in the SREBP path-
way. Insig-2 may play a more important role than Insig-1 in the
Figure 7. Model for convergent feedback inhibition of cholesterol synthesis and
uptake
The essential feature of the model is that SREBP processing will not be blocked
by sterols unless two SREBP-induced products converge on Scap simulta-
neously: (1) newly synthesized Insig-1 and (2) newly synthesized or acquired cho-
lesterol. This convergence assures that SREBP processing will not be terminated
before the cholesterol needs of the cell are met.22liver, where higher amounts of Insig-2 are produced through
the action of a liver-specific promoter that is downregulated
by insulin (Yabe et al., 2003).
The ubiquitination and degradation of Insig-1 in sterol-
deprived cells stand in striking contrast to the Insig-1-dependent
ubiquitination and degradation of the cholesterol biosynthetic
enzyme HMG CoA reductase that occurs only in sterol-over-
loaded cells. DeBose-Boyd and coworkers have shown that
sterols induce the binding of ER-embedded HMG CoA reduc-
tase to Insig-1, and this interaction induces the ubiquitination
and degradation of the reductase (Sever et al., 2003). Recently,
they have shown that ubiquitination ismediatedbygp78, amem-
brane bound ubiquitin transferase (E3) that forms a complexwith
Insig-1 (Song et al., 2005). In the presence of sterols, this bound
gp78 ubiquitinates HMG CoA reductase. It is tempting to spec-
ulate that in the absence of sterols, when neither Scap nor
HMG CoA reductase is bound to Insig-1, gp78 ubiquitinates In-
sig-1, accelerating its degradation. When sterols induce HMG
CoA reductase tobind to Insig-1, theubiquitination reaction is di-
verted toward HMG CoA reductase. On the other hand, when
sterols induce Scap to bind to Insig-1, the gp78 no longer ubiq-
uitinates Insig-1. Perhaps Scap displaces gp78 from Insig-1 in
a sterol-dependent reaction.
Both Scap and HMG CoA reductase bind to Insigs in a sterol-
dependent fashion by virtue of their shared sterol-sensing do-
mains, which comprise transmembrane helices 2–6 in both pro-
teins. Other proteins have conserved sterol-sensing domains,
including Patched (the receptor for the cholesterol-modified
morphogen Hedgehog), the Neimann-Pick C1 protein (NPC1)
(which functions in intracellular cholesterol transport), and the
Neimann-Pick C1-like protein (NPC1L1) (which functions in the
intestinal absorption of cholesterol) (Kuwabara and Labouesse,
2002; Altmann et al., 2004). Whether these proteins interact with
Insigs in a sterol-dependent manner so as to affect their stability
is currently unknown, but the issue should be explored.
Experimental procedures
Materials and antibodies
These sections are described in the Supplemental Data.
Plasmid constructs
The following recombinant expression plasmidshave beendescribed: pEF1a-
HA-ubiquitin (provided by Dr. Zhijian Chen, University of Texas Southwestern
Medical Center), encoding amino acids 1–76 of human ubiquitin preceded
by an epitope tag derived from the influenza hemagglutinin (HA) protein
(YPYDVPDY) under control of the EF1a promoter (Kanayama et al., 2004);
pCMV-Insig1-T7,encodinghuman Insig-1 followedby threecopiesofaT7epi-
tope tag (MASMTGGQQMG) under control of the cytomegalovirus (CMV) pro-
moter (Song et al., 2005); pCMV-Scap, encoding wild-type hamster Scap
under control of the CMV promoter (Sakai et al., 1997); and pTK-Scap and
pTK-Scap(Y298C), encodingwild-typeandmutant hamsterScap, respectively,
under control of the thymidine kinase (TK) promoter (Nohturfft et al., 1998).
pTK-Insig1-Myc encoding wild-type human Insig-1 followed by six tan-
dem copies of a c-Myc epitope tag (EQKLISEEDL) under control of the TK
promoter was generated as described in the Supplemental Data. pTK-
Insig1(K156R/K158R)-Myc and pCMV-Insig1(K156R/K158R)-T7 were gen-
erated by site-directed mutagenesis using the QuikChange Site-Directed
Mutagenesis Kit (Stratagene). The coding regions of all plasmids were se-
quenced before use.
Tissue culture media
Medium A contained a 1:1 mixture of Ham’s F-12 medium and Dulbecco’s
modified Eagle’s medium supplemented with 100 units/ml penicillin andCELL METABOLISM : JANUARY 2006
Sterol-regulated degradation of Insig-1100 mg/ml streptomycin sulfate. Medium B contained medium A supple-
mented with 5% (v/v) newborn calf LPDS, 50 mM sodium compactin, and
50 mM sodium mevalonate. Medium C contained medium A supplemented
with 5% (v/v) fetal calf serum, 5 mg/ml cholesterol, 1 mM sodiummevalonate,
and 20 mM sodium oleate. Medium D contained methionine- and cysteine-
free RPM1 1640 medium supplemented with 5% newborn calf LPDS,
50 mM sodium compactin, and 50 mM sodium mevalonate.
Cell culture
Cells were maintained in monolayer culture at 37ºC in 8%–9% CO2. CHO-7
cells are a clone of CHO-K1 cells selected for growth in LPDS (Metherall
et al., 1989). SRD-13A cells (Scap2/2) (Rawson et al., 1999) and SRD-14 cells
(Insig-12/2) (Sever et al., 2004) are mutant cells derived from CHO-7 cells.
SRD-14/pTK-Insig1-Myc cells are a clone of SRD-14 cells stably transfected
with pTK-Insig1-Myc (see below). SRD-14/pTK-Insig1(K156R/K158R)-
Myc cells are a clone of SRD-14 cells stably transfected with pTK-
Insig1(K156R/K158R)-Myc (see below).
Stock cultures of CHO-7 cells weremaintained inmediumA supplemented
with 5% newborn calf LPDS. SRD-13A cells were maintained in medium C.
SRD-14/pTK-Insig1-Myc cells and SRD-14/pTK-Insig1(K156R/K158R)-Myc
cells were maintained in medium A supplemented with 5% LPDS and
500 mg/ml G418.
Transient transfection of cells
SRD-13A cells were transiently transfected with FuGENE 6 reagent (Roche
Applied Science) according to themanufacturer’s protocol. The total amount
of DNA in each transfection was adjusted to 3 mg per dish by addition of
pcDNA3 mock vector. Conditions of incubation after transfection are de-
scribed in the Figure legends. At the end of the incubation, duplicate dishes
of cells for each variable were harvested and pooled for analysis.
Stable transfection of cells
SRD-14/pTK-Insig1-Myc and SRD-14/pTK-Insig1(K156R/K158R)-Myc cells,
derivatives of SRD-14 cells, were generated as follows. On day 0, SRD-14
cells were set up at 5 3 105 cells per 100 mm dish in medium A with 5%
LPDS. On day 1, the cells were transfected with 1 mg of pTK-Insig1-Myc or
pTK-Insig1(K156R/K158R)-Myc using the FuGENE 6 transfection reagent
as described above. On day 2, the cells were switched to medium A supple-
mented with 5% LPDS and 700 mg/ml G418. Fresh mediumwas added every
2–3 days until colonies formed after about 2 weeks. Individual colonies were
isolated with cloning cylinders, and Insig-1 expression was assessed by im-
munoblot analysis with anti-Myc. Cells were chosen based on their trans-
gene expression such that Insig-1 expression level in SRD-14/pTK-Insig1-
Myc cells is equal to that in SRD-14/pTK-Insig1(K156R/K158R)-Myc cells
in the presence of 1 mg/ml of 25-HC. Cells from single colonies were cloned
by limiting dilution and maintained in medium A containing 5% LPDS and
500 mg/ml G418.
Immunoblot analysis, immunoprecipitation, and real-time PCR
These methods are described in the Supplemental Data.
Pulse-chase analysis in CHO-7 cells
CHO-7 cells were incubated in medium B as described above. Sixteen hours
after incubation, the cells were washed with phosphate-buffered saline and
switched to methionine- and cysteine-free medium D. After 1 hr at 37ºC,
the cells were pulse labeled with 200 mCi/ml 35S Protein LabelingMix (Perkin-
Elmer Life Sciences) in 1.5 ml of medium D. After labeling for 1 hr, the me-
dium was removed, and the cells were washed twice with phosphate-buff-
ered saline and chased for various times in medium B (containing 0.12 mM
unlabeled methionine and 0.4 mM unlabeled cysteine) in the absence or
presence of 1 mg/ml 25-HC. Following the chase, the medium was removed,
and the cells were washed three times with cold phosphate-buffered saline
and lysed in 1 ml of buffer B (50 mM Tris-HCl [pH 7.2], 150 mM NaCl,
0.5% [v/v] Fos-choline 13, and protease inhibitor cocktail). The lysates
were clarified by centrifugation at 20,0003 g for 20 min at 4ºC. The superna-
tants (1 ml) were transferred to fresh tubes and precleared by rotation for
16 hr at 4ºCwith 50 ml of protein A/G agarose (Santa Cruz) and 20 mg/ml con-
trol nonimmune IgG. After centrifugation at 300 3 g for 7 min at 4ºC, the
supernatants were transferred to fresh tubes, and 10 ml of polyclonal antise-
rum against Insig-1 (1:100 dilution) together with 50 ml of protein A/G agaroseCELL METABOLISM : JANUARY 2006beads was added and rotated for 2 hr at 4ºC. The beads were collected by
centrifugation, washed six times (30 min each) in 1 ml of buffer B, resus-
pended in 50 ml of 13 SDS loading buffer, and boiled for 5 min. After centri-
fugation at 16,0003 g for 5 min at room temperature, the supernatants were
transferred to fresh tubes, and aliquots of the immunoprecipitates were sub-
jected to SDS-PAGE. Radiolabeled proteins were transferred to Hybond
C-Extra nitrocellulose filters. The filters were dried, exposed to an imaging
plate at room temperature for 24 hr, and scanned in a Molecular Dynamics
Storm 820 phosphorimaging device.
Ubiquitination of Insig-1
Cells were lysed in 0.1 ml of buffer B supplemented with 10 mM N-ethylma-
leimide, rotated at 4ºC for 1 hr, and centrifuged at 100,000 3 g for 15 min at
4ºC. The resulting supernatants were mixed with 0.3 ml of 8 M urea in buffer
B, rotated for 10 min at room temperature, diluted with buffer B to decrease
the urea concentration to 2M, and subjected to immunoprecipitation (16 hr at
4ºC) with 50 ml of monoclonal anti-T7 IgG-coupled agarose beads (Novagen)
directed against the T7 epitope tag on Insig-1, followed by low-speed centri-
fugation. The resulting supernatants were mixed with 53 SDS loading buffer,
and the pelleted beads were washed three times (20 min each) with buffer B
and resuspended in 50 ml of 13 SDS loading buffer. The supernatant and pel-
let fractions were boiled for 5 min and subjected to SDS-PAGE and immuno-
blotting with an antibody against the HA tag on ubiquitin.
Supplemental data
Supplemental Data include Supplemental Experimental Procedures and
Supplemental References and can be found with this article online at
http://www.cellmetabolism.org/cgi/content/full/3/1/15/DC1/.
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